A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1




TekijätReinholm, Arttu; Khan, Hira; Laakso, Terhi; Maljanen, Sari; Jalkanen, Pinja; Gunell, Marianne; Kallonen, Teemu; Österlund, Pamela; Ritvos, Olli; Nousiainen, Arttu; Häkkinen, Hanni K.; Pakkanen, Sari H.; Välimaa, Hanna; Kantele, Anu; Lempainen, Johanna; Julkunen, Ilkka; Kolehmainen, Pekka; Kakkola, Laura

KustantajaElsevier

Julkaisuvuosi2025

Lehti:Vaccine

Artikkelin numero127894

Vuosikerta68

DOIhttps://doi.org/10.1016/j.vaccine.2025.127894

Verkko-osoitehttps://doi.org/10.1016/j.vaccine.2025.127894

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/505142362


Tiivistelmä

The long-term effectiveness of COVID-19 vaccines remains a critical area of study, especially with the emergence of new SARS-CoV-2 subvariants. In this study, we investigated the long-term neutralization capacity of SARS-CoV-2 -specific antibodies induced by the third, fourth and fifth vaccine doses, and by SARS-CoV-2 breakthrough infections. Spike (S)-specific antibodies decline relatively rapidly after each vaccine dose, with an estimated half-life of 3–4 months. However, after the third vaccine dose, S-specific serum antibody levels remained comparable at 12 and 24 months post-vaccination. Antibody levels induced by the fourth and fifth vaccine doses were higher, and the decay was slower than after the third vaccine dose. Additionally, nucleocapsid (N)-specific antibody levels increased significantly following multiple breakthrough infections. The neutralization capacity of the antibodies against Omicron XBB.1.5 and JN.1 subvariants were significantly increased by the fifth, XBB.1.5 subvariant specific, mRNA vaccine dose. Our findings strongly indicate that updated booster vaccines based on the latest s of concern are necessary to sustain high neutralizing antibody levels against emerging variants. No exhaustion of vaccine-induced antibody response was observed after repeated COVID-19 vaccinations.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This work was supported by the Academy of Finland (grant numbers 337530 and 339512), Jane and Aatos Erkko Foundation (grant numbers 5360-cc2fc and 230031), and the Sigrid Jusélius Foundation.


Last updated on 2025-07-11 at 09:33